: The AMEDEO Literature Guide

Home

Fast Track

My Amedeo

FAQ

About

Flying Publisher

	Fast Track

FPG #8: Alternative Treatments in Psychiatry
FPG #7: Critical Care in Neurology

Free Medical Books

Ovarian Neoplasms

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 392 articles:
HTML format
Text format

Single Articles

February 2012

PENNINGTON KP , Swisher EM
Hereditary ovarian cancer: Beyond the usual suspects.
Gynecol Oncol. 2012;124:347-53.
PubMed Text format Related articles Abstract available

NELSON BH
Killer T cells to the rescue in ovarian cancer.
Gynecol Oncol. 2012;124:178-9.
PubMed Text format Related articles

January 2012

SONG T , Choi CH, Cho YJ, Sung CO, et al
Expression of 67-kDa laminin receptor was associated with tumor progression and poor prognosis in epithelial ovarian cancer.
Gynecol Oncol. 2012.
PubMed Text format Related articles Abstract available

CLIBY W , Aletti G, Chi D, Bristow R, et al
RE: Defining the limits of radical cytoreductive surgery in ovarian cancer.
Gynecol Oncol. 2012.
PubMed Text format Related articles

LIM MC , Park SY
Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy.
Gynecol Oncol. 2012.
PubMed Text format Related articles

RUBATT JM , Darcy KM, Tian C, Muggia F, et al
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study.
Gynecol Oncol. 2012.
PubMed Text format Related articles Abstract available

POURGHOLAMI MH , Mekkawy AH, Badar S, Morris DL, et al
Minocycline inhibits growth of epithelial ovarian cancer.
Gynecol Oncol. 2012.
PubMed Text format Related articles Abstract available

ANSALONI L , De Iaco P, Frigerio L
Re: "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial." - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperi
Gynecol Oncol. 2012.
PubMed Text format Related articles

THRALL MM , Gray HJ, Goff BA
Letter-to-the Editor "Trends in treatment of advanced epithelial ovarian cancer in the Medicare population"
Gynecol Oncol. 2012.
PubMed Text format Related articles

BURGER RA
Advances in ovarian cancer disease control.
Gynecol Oncol. 2012;124:5-9.
PubMed Text format Related articles

VERGOTE I , Leunen K, Amant F
Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?
Gynecol Oncol. 2012;124:1-2.
PubMed Text format Related articles

MUTCH DG
The more things change the more they stay the same.
Gynecol Oncol. 2012;124:3-4.
PubMed Text format Related articles

December 2011

SCHMELER KM , Sood AK, Bell-McGuinn KM, Coleman RL, et al
Proceedings from the 9th International Conference on Ovarian Cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

XU JL , Commins J, Partridge E, Riley TL, et al
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BARLIN JN , Yu C, Hill EK, Zivanovic O, et al
Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

WHITWORTH JM , Londono-Joshi AI, Sellers JC, Oliver PJ, et al
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

STAVRAKA C , Ford A, Ghaem-Maghami S, Crook T, et al
A study of symptoms described by ovarian cancer survivors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SUNDAR S , Wu J, Hillaby K, Yap J, et al
A systematic review evaluating the relationship between Progression free survival and Post Progression survival in advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SCHUMMER M , Drescher C, Forrest R, Gough S, et al
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Gynecol Oncol. 2011.
PubMed Text format Related articles

MARKMAN M
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Gynecol Oncol. 2011.
PubMed Text format Related articles

ARMSTRONG DK , Visvanathan K
The "luxury" of second malignancies.
Gynecol Oncol. 2011;123:453-4.
PubMed Text format Related articles

November 2011

FAIRFIELD KM , Murray KM, Wierman HR, Han PK, et al
Disparities in Hospice Care among Older Women Dying with Ovarian Cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

RANDALL LM , Sill MW, Burger RA, Monk BJ, et al
Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VON GRUENIGEN VE , Huang HQ, Gil KM, Frasure HE, et al
The Association Between Quality of Life Domains and Overall Survival in Ovarian Cancer Patients During Adjuvant Chemotherapy: A Gynecologic Oncology Group Study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PAXTON RJ , Garcia-Prieto C, Berglund M, Hernandez M, et al
A randomized parallel-group dietary study for stage ii-iv ovarian cancer survivors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MENG E , Taylor B, Ray A, Shevde LA, et al
Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MONTAVON C , Gloss BS, Warton K, Barton CA, et al
Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TIAN C , Ambrosone CB, Darcy KM, Krivak TC, et al
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

COLOMBO N , Mangili G, Mammoliti S, Kalling M, et al
A phase II study of aflibercept in patients with advainced epithelial ovarian cancer and symptomatic malignant ascites.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TERPLAN M , Schluterman N, McNamara EJ, Tracy JK, et al
Have racial disparities in ovarian cancer increased over time? An analysis of SEER data.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CORREA DD , Hess LM
Cognitive Function and Quality of Life in Ovarian Cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KOLOMAINEN DF , Daponte A, Barton DP, Pennert K, et al
Outcomes of surgical management of bowel obstruction in relapsed Epithelial Ovarian Cancer (EOC).
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VOGL TJ , Naguib NN, Lehnert T, Nour-Eldin NE, et al
Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient's management.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GOFF BA , Lowe KA, Kane JC, Robertson MD, et al
Symptom Triggered Screening for Ovarian Cancer: A Pilot Study of Feasibility and Acceptability.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

NAGEL CI , Backes FJ, Hade EM, Cohn DE, et al
Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

DALTON HJ , Yu X, Hu L, Kapp DS, et al
An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HENRETTA MS , Anderson CL, Angle JF, Duska LR, et al
It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.
Gynecol Oncol. 2011;123:342-5.
PubMed Text format Related articles Abstract available

October 2011

RODRIGUEZ AO , Llacuachaqui M, Pardo GG, Royer R, et al
BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ANDERSEN MR , Sweet E, Lowe KA, Standish LJ, et al
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HWANG WT , Adams SF, Tahirovic E, Hagemann IS, et al
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FANNING J , Hossler CA, Kesterson JP, Donahue RN, et al
Expression of the Opioid Growth Factor- Opioid Growth Factor Receptor Axis in Human Ovarian Cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MEISER B , Gleeson M, Kasparian N, Barlow-Stewart K, et al
There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

RUNGRUANG B , Miller A, Richard SD, Hamilton CA, et al
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MUNKSGAARD PS , Blaakaer J
The association between endometriosis and ovarian cancer: A review of histological, genetic and molecular alterations.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GARDNER GJ , Baser RE, Brady MF, Bristow RE, et al
CA125 Regression in Ovarian Cancer Patients Treated with Intravenous versus Intraperitoneal Platinum-Based Chemotherapy: A Gynecologic Oncology Group Study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GUNTUPALLI SR , Zighelboim I, Kizer NT, Zhang Q, et al
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

O'MALLEY DM
Response to letter to the editor in response to "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer"
Gynecol Oncol. 2011.
PubMed Text format Related articles

ALTUNTAS CZ , Jaini R, Kesaraju P, Jane-Wit D, et al
Autoimmune mediated regulation of ovarian tumor growth.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

YANG C , Cai J, Wang Q, Tang H, et al
Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ELATTAR A , Warburton KG, Mukhopadhyay A, Freer RM, et al
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LIFFORD KJ , Fraser L, Rosenthal AN, Rogers MT, et al
Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS).
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ROMERO IL , Lee W, Mitra AK, Gordon IO, et al
The effects of 17beta-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KLEPPE M , Wang T, Van Gorp T, Slangen BF, et al
Lymph node metastasis in stages I and II ovarian cancer: A review.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TANNER EJ , Black DR, Zivanovic O, Kehoe SM, et al
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BRUNNER A , Hinterholzer S, Riss P, Heinze G, et al
Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GORDON AN , Teneriello M, Janicek MF, Hines J, et al
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KARST AM , Levanon K, Duraisamy S, Liu JF, et al
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Gynecol Oncol. 2011;123:5-12.
PubMed Text format Related articles Abstract available

September 2011

WRIGHT JD , Lewin SN, Deutsch I, Burke WM, et al
Defining the limits of radical cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BONDURANT AE , Huang Z, Whitaker RS, Simel LR, et al
Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

RAMASUBBAIAH R , Perkins SM, Schilder J, Whalen C, et al
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HIGASHI M , Kajiyama H, Shibata K, Mizuno M, et al
Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

POKRZYWINSKI R , Secord AA, Havrilesky LJ, Puls LE, et al
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: Results from a randomized clinical trial.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

THRALL MM , Gray HJ, Symons RG, Weiss NS, et al
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

YANG YI , Kim JH, Lee KT, Choi JH, et al
Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ADAMS SF , Marsh EB, Elmasri W, Halberstadt S, et al
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HAMILTON CA , Krivak TC, Maxwell GL
Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology.
Gynecol Oncol. 2011.
PubMed Text format Related articles

CARSER JE , Quinn JE, Michie CO, O'Brien EJ, et al
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SHIH KK , Garg K, Soslow RA, Chi DS, et al
Accuracy of frozen section diagnosis of ovarian borderline tumor.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PARK JY , Kim DY, Kim JH, Kim YM, et al
Micropapillary pattern in serous borderline ovarian tumors: Does it matter?
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CHI DS , Musa F, Dao F, Zivanovic O, et al
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ALVAREZ SECORD A , Darcy KM, Hutson A, Huang Z, et al
The regulation of MASPIN expression in epithelial ovarian cancer: Association with p53 status, and MASPIN promoter methylation: A Gynecologic Oncology Group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CHO JA , Park H, Lim EH, Kim KH, et al
Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

COHN DE
What does cost have to do with it?
Gynecol Oncol. 2011;122:465-6.
PubMed Text format Related articles

GERSHON R , Aviel-Ronen S, Korach J, Daniel-Carmi V, et al
FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors.
Gynecol Oncol. 2011;122:580-4.
PubMed Text format Related articles Abstract available

August 2011

COTICCHIA CM , Curatolo AS, Zurakowski D, Yang J, et al
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MANNEL RS
Anti-angiogenic therapy in ovarian cancer; what is the best population?
Gynecol Oncol. 2011.
PubMed Text format Related articles

JUDSON PL , Dickson EL, Argenta PA, Xiong Y, et al
A prospective, randomized trial of integrative medicine for women with ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VOSS MA , Ganesan R, Ludeman L, McCarthy K, et al
Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FERRERO A , Dompe D, Ravarino N, Ramella A, et al
Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

AKHTAR-DANESH N , Elit L, Lytwyn A
Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: A population-based study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HYMAN DM , Zhou Q, Arnold AG, Grisham RN, et al
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VAY A , Kumar S, Seward S, Semaan A, et al
Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: An epidemiological analysis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SANDADI S , Frasure HE, Broderick MJ, Waggoner SE, et al
The effect of sleep disturbance on quality of life in women with ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HOGDALL C , Fung ET, Christensen IJ, Nedergaard L, et al
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CHUA TC
Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology.
Gynecol Oncol. 2011.
PubMed Text format Related articles

DIZON DS , Sill MW, Gould N, Rubin SC, et al
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TEWARI KS , Monk BJ
American society of clinical oncology 2011 annual meeting update: summary of selected gynecologic cancer abstracts.
Gynecol Oncol. 2011;122:209-12.
PubMed Text format Related articles

EDWARDS RP
Is hyperthermic intraoperative peritoneal chemotherapy and systemic chemotherapy as effective as standard intraperitoneal chemotherapy: time for a prospective trial?
Gynecol Oncol. 2011;122:207-8.
PubMed Text format Related articles

CHAPMAN JS , Powell CB, McLennan J, Crawford B, et al
Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
Gynecol Oncol. 2011;122:339-43.
PubMed Text format Related articles Abstract available

July 2011

BRARD L , Lange TS, Robison K, Kim KK, et al
Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BODMER M , Becker C, Meier C, Jick SS, et al
Use of metformin and the risk of ovarian cancer: A case-control analysis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LANGSTRAAT C , Aletti GD, Cliby WA
Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MARKMAN M
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

DUTTA S , Wang FQ, Wu HS, Mukherjee TJ, et al
The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GAYAR OH , Robbins JR, Parikh K, Lu M, et al
Hysterectomy for uterine adenocarcinoma in the elderly: Tumor characteristics, and long-term outcome.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BIGE O , Demir A, Saygili U, Gode F, et al
Frozen section diagnoses of 578 ovarian tumors made by pathologists with and without expertise on gynecologic pathology.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VICUS D , Beiner ME, Clarke B, Klachook S, et al
Ovarian immature teratoma: Treatment and outcome in a single institutional cohort.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

NAKAMURA K , Hongo A, Kodama J, Hiramatsu Y, et al
The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BAMIAS A , Karadimou A, Soupos N, Sotiropoulou M, et al
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TEOH D , Berchuck A, Secord AA, Lee PS, et al
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BEHBAKHT K , Sill MW, Darcy KM, Rubin SC, et al
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SHIH KK , Garg K, Levine DA, Kauff ND, et al
Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

REIN DT , Volkmer A, Beyer IM, Curiel DT, et al
Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GIATROMANOLAKI A , Koukourakis MI, Koutsopoulos A, Chloropoulou P, et al
High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FANNING J , Yacoub E, Hojat R
Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: Success, morbidity and survival.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

OLIVER KE , Enewold LR, Zhu K, Conrads TP, et al
Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BAUMANN K , Pfisterer J, Wimberger P, Burchardi N, et al
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KING ER , Zu Z, Tsang YT, Deavers MT, et al
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

Retraction to "A3' UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer" [Gynecol. Oncol. 120 (2011) S3].
Gynecol Oncol. 2011;122:205.
PubMed Text format Related articles

June 2011

BODNAR L , Gornas M, Szczylik C
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MA X , Zhang J, Liu S, Huang Y, et al
Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CLARKE CH , Yip C, Badgwell D, Fung ET, et al
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LU D , Kuhn E, Bristow RE, Giuntoli RL 2nd, et al
Comparison of candidate serologic markers for type I and type II ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FURUYA M , Yoneyama T, Miyagi E, Tanaka R, et al
Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HAMILTON CA , Miller A, Miller C, Krivak TC, et al
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HOSKINS E , Rodriguez-Canales J, Hewitt SM, Elmasri W, et al
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LESNOCK JL , Farris C, Krivak TC, Smith KJ, et al
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

DE STEFANO I , Zannoni GF, Prisco MG, Fagotti A, et al
Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

DERACO M , Kusamura S, Virzi S, Puccio F, et al
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

COLOMBO PE , Boustta M, Poujol S, Jarlier M, et al
Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: Experimental study in a murine model of ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

POVEDA A , Kaye SB, McCormack R, Wang S, et al
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LANDRUM LM , Hyde J Jr, Mannel RS, McMeekin DS, et al
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SHIH KK , Yun E, Gardner GJ, Barakat RR, et al
Surgical cytoreduction in stage IV endometrioid endometrial carcinoma.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FAUCI JM , Whitworth JM, Schneider KE, Subramaniam A, et al
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ITAMOCHI H , Yoshida T, Walker CL, Bartholomeusz C, et al
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BAST RC JR , Spriggs DR
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis.
Gynecol Oncol. 2011;121:429-30.
PubMed Text format Related articles

LEBLANC E , Narducci F, Farre I, Peyrat JP, et al
Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.
Gynecol Oncol. 2011;121:472-6.
PubMed Text format Related articles Abstract available

RABBAN JT , Mackey A, Powell CB, Crawford B, et al
Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.
Gynecol Oncol. 2011;121:466-71.
PubMed Text format Related articles Abstract available

WATANABE T , Matsuda K, Ishihara S
Heterogeneous distribution of LOH (loss of heterozygosity) and tumor progression.
Gynecol Oncol. 2011;121:640.
PubMed Text format Related articles

LEE YY , Kim TJ, Kim MJ, Kim HJ, et al
Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

May 2011

POWLESS CA , Aletti GD, Bakkum-Gamez JN, Cliby WA, et al
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BRISTOW RE , Ueda S, Gerardi MA, Ajiboye OB, et al
Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a Tertiary Gynecologic Oncology Referral Center.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MARTIGNETTI JA , Dottino PR
Response to the Letter to the Editor by Bol and van Diest regarding the review article "BRCA1 methylation and BRCA1 mutations in ovarian cancer"
Gynecol Oncol. 2011.
PubMed Text format Related articles

PELLICCIOTTA I , Yang CP, Goldberg GL, Shahabi S, et al
Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

JIANG Z , Fletcher NM, Ali-Fehmi R, Diamond MP, et al
Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MARKMAN M
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: A phase II study of the Gynecologic Oncology Group.
Gynecol Oncol. 2011.
PubMed Text format Related articles

DRENZEK JG , Seiler NL, Jaskula-Sztul R, Rausch MM, et al
Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LEE CW , Chuang LS, Kimura S, Lai SK, et al
RUNX3 functions as an oncogene in ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KUDOH K , Takano M, Kouta H, Kikuchi R, et al
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VON GRUENIGEN VE , Frasure HE, Kavanagh MB, Lerner E, et al
Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TAO T , Yang JX, Cao DY, Liu JT, et al
Management of recurrent endodermal sinus tumor of the ovary associated with pregnancy.
Gynecol Oncol. 2011.
PubMed Text format Related articles

GUERRA F , Kurelac I, Magini P, Cormio A, et al
Mitochondrial DNA genotyping reveals synchronous nature of simultaneously detected endometrial and ovarian cancers.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

JOLY F , Ray-Coquard I, Fabbro M, Donoghoe M, et al
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KAJIYAMA H , Shibata K, Mizuno M, Nawa A, et al
Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LU L , Schwartz P, Scarampi L, Rutherford T, et al
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PRIEBE A , Tan L, Wahl H, Kueck A, et al
Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LEE YY , Choi CH, Do IG, Song SY, et al
Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CRESS RD , Leiserowitz GS
Re: Surgical staging of early stage epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

MARKMAN M
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown.
Gynecol Oncol. 2011.
PubMed Text format Related articles

HERZOG TJ , Vermorken JB, Pujade-Lauraine E, Provencher DM, et al
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FAGOTTI A , Costantini B, Vizzielli G, Perelli F, et al
HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome.
Gynecol Oncol. 2011.
PubMed Text format Related articles

CLIBY B
CA125 surveillance and outcomes at secondary surgery: more here than meets the eye.
Gynecol Oncol. 2011;121:245-6.
PubMed Text format Related articles

April 2011

LEE M , Kim SW, Nam EJ, Yim GW, et al
The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

DONAHUE RN , McLaughlin PJ, Zagon IS
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Gynecol Oncol. 2011.
PubMed Text format Related articles

HUNTSMAN DG , Gilks CB
Surgical staging of early stage epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

WU Q , Guo R, Lin M, Zhou B, et al
MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2.
Gynecol Oncol. 2011.
PubMed Text format Related articles

MANNEL RS , Brady MF, Kohn EC, Hanjani P, et al
A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study.
Gynecol Oncol. 2011.
PubMed Text format Related articles

WEROHA SJ , Oberg AL, Ziegler KL, Dakhilm SR, et al
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Gynecol Oncol. 2011.
PubMed Text format Related articles

MYLONAS I , Matsingou C, Kaufl SD, Bruning A, et al
Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: From immunohistochemistry to clinical testing?
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TODO Y , Kato H, Okamoto K, Minobe S, et al
Incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes in intermediate- and high-risk endometrial cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SCHULTZ KA , Pacheco MC, Yang J, Williams GM, et al
Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: A report from the International Pleuropulmonary Blastoma Registry.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BASHA R , Ingersoll SB, Sankpal UT, Ahmad S, et al
Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

THRALL MM , Gray HJ, Symons RG, Weiss NS, et al
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

COLEMAN RL , Brady WE, McMeekin DS, Rose PG, et al
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KRIVAK TC , Darcy KM, Tian C, Bookman M, et al
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SONG T , Choi CH, Kim HJ, Kim MK, et al
Accuracy of frozen section diagnosis of borderline ovarian tumors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

THRALL MM , Paley P, Pizer E, Garcia R, et al
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MERY E , Jouve E, Guillermet S, Bourgognon M, et al
Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

AL-BARRAK J , Santos JL, Tinker A, Hoskins P, et al
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

March 2011

MAXWELL GL , Hood BL, Day R, Chandran U, et al
Proteomic analysis of stage I endometrial cancer tissue: Identification of proteins associated with oxidative processes and inflammation.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

VARUGHESE J , Cocco E, Bellone S, Bellone M, et al
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GEOMINI PM , Kruitwagen RF, Bremer GL, Massuger L, et al
Should we centralise care for the patient suspected of having ovarian malignancy?
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PAULSEN T , Kaern J, Trope C
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

WRIGHT JD , Lewin SN, Barrena Medel NI, Sun X, et al
Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

THERIAULT C , Pinard M, Comamala M, Migneault M, et al
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

JACOB F , Meier M, Caduff R, Goldstein D, et al
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

RAUH-HAIN JA , Growdon WB, Rodriguez N, Goodman AK, et al
Carcinosarcoma of the ovary: A case-control study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HARTER P , Muallem ZM, Buhrmann C, Lorenz D, et al
Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

USHA L , Sill MW, Darcy KM, Benbrook DM, et al
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LE T , Latifah H, Jolicoeur L, Weberpals J, et al
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FAGOTTI A , Vizzielli G, Scambia G
RE: "Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers"
Gynecol Oncol. 2011.
PubMed Text format Related articles

YASMEEN A , Beauchamp MC, Piura E, Segal E, et al
Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KETABI Z , Bartuma K, Bernstein I, Malander S, et al
Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TANYI JL , McCann G, Hagemann AR, Coukos G, et al
Clinical predictors of bevacizumab-associated gastrointestinal perforation.
Gynecol Oncol. 2011;120:464-9.
PubMed Text format Related articles Abstract available

February 2011

SHIH KK , Qin LX, Tanner EJ, Zhou Q, et al
A microRNA survival signature (MiSS) for advanced ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PARKINSON CA , Hatcher HM, Earl HM, Ajithkumar TV, et al
Multidisciplinary management of malignant ovarian germ cell tumours.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

PHIPPEN NT , Lowery WJ, Banks NB, Leath CA 3rd, et al
Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation.
Gynecol Oncol. 2011.
PubMed Text format Related articles

YIN L , Grandi N, Raum E, Haug U, et al
Meta-analysis: Circulating vitamin D and ovarian cancer risk.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ZHANG S , Royer R, Li S, McLaughlin JR, et al
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

HOLMBERG LA , Goff B, Veljovich D
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles

O'MALLEY DM , Richardson DL, Rheaume PS, Salani R, et al
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FARLEY J , Smith LM, Darcy KM, Brady MF, et al
Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FLEMING ND , Cass I, Walsh CS, Karlan BY, et al
CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ATTIAS-GEVA Z , Bentov I, Fishman A, Werner H, et al
Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MARTINEZ A , Pomel C, Mery E, Querleu D, et al
Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ROSE PG , Brady MF
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?
Gynecol Oncol. 2011;120:300-1.
PubMed Text format Related articles

January 2011

BRISTOW RE , Zahurak ML, Ibeanu OA
Racial disparities in ovarian cancer surgical care: A population-based analysis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

AUNE G , Lian AM, Tingulstad S, Torp SH, et al
Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MORGAN MA , Sill MW, Fujiwara K, Greer B, et al
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CHEN J , Wang L, Matyunina LV, Hill CG, et al
Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SONG YJ , Lim MC, Kang S, Seo SS, et al
Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

MANGILI G , Sigismondi C, Lorusso D, Cormio G, et al
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

NO JH , Jeon YT, Park IA, Kim YB, et al
Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LACOUR RA , Westin SN, Meyer LA, Wingo SN, et al
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ANGLESIO MS , Carey MS, Kobel M, Mackay H, et al
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

DOS SANTOS LA , Garg K, Diaz JP, Soslow RA, et al
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BELL-MCGUINN KM , Matthews CM, Ho SN, Barve M, et al
A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

KOBAYASHI Y , Seino KI, Hosonuma S, Ohara T, et al
Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

LACHANCE JA , Choudhri AF, Sarti M, Modesitt SC, et al
A nomogram for estimating the probability of ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

CRESS RD , Bauer K, O'Malley CD, Kahn AR, et al
Surgical staging of early stage epithelial ovarian cancer: Results from the CDC-NPCR ovarian patterns of care study.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

WEINBERG LE , Lurain JR, Singh DK, Schink JC, et al
Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

ZEIMET AG , Fiegl H, Goebel G, Kopp F, et al
DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

GELLER MA , Ivy JJ, Ghebre R, Downs LS Jr, et al
A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TAPIA V , Gabler F, Munoz M, Yazigi R, et al
Tyrosine kinase A receptor (trkA): A potential marker in epithelial ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BAKHRU A , Buckanovich RJ, Griggs JJ
The impact of diabetes on survival in women with ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

FINCH A , Metcalfe KA, Chiang JK, Elit L, et al
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BURGER RA
Overview of anti-angiogenic agents in development for ovarian cancer.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BIJEN CB , Vermeulen KM, Mourits MJ, Arts HJ, et al
Cost effectiveness of laparoscopy versus laparotomy in early stage endometrial cancer: A randomised trial.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

BEVIS KS , McNally LR, Sellers JC, Della Manna D, et al
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

TEOH D , Ayeni TA, Rubatt JM, Adams DJ, et al
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Gynecol Oncol. 2011.
PubMed Text format Related articles Abstract available

SWISHER EM
Granulin: biomarker or interesting window into host/tumor biology?
Gynecol Oncol. 2011;120:1-2.
PubMed Text format Related articles

CHANG HL , Pieretti-Vanmarcke R, Nicolaou F, Li X, et al
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Gynecol Oncol. 2011;120:128-34.
PubMed Text format Related articles Abstract available

December 2010

BOL GM , van Diest PJ
BRCA1 methylation and BRCA1 mutations in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles

MAGRINA JF , Zanagnolo V, Noble BN, Kho RM, et al
Robotic approach for ovarian cancer: Perioperative and survival results and comparison with laparoscopy and laparotomy.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TODO Y , Kato H, Minobe S, Okamoto K, et al
A validation study of the new revised FIGO staging system to estimate prognosis for patients with stage IIIC endometrial cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HOU J , Goldberg GL, Qualls CR, Kuo DY, et al
Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): A pooled analysis.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KIM PS , Djazayeri S, Zeineldin R
Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HERZOG TJ , Sill MW, Walker JL, O'Malley D, et al
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q).
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SEMAAN A , Munkarah AR, Arabi H, Bandyopadhyay S, et al
Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SEIDMAN JD , Zhao P, Yemelyanova A
"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TAIT DL , Blessing JA, Hoffman JS, Moore KN, et al
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SHIH KK , Zhou Q, Huh J, Morgan JC, et al
Risk factors for recurrence of ovarian borderline tumors.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KRILL LS , Ueda SM, Gerardi M, Bristow RE, et al
Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

NYANTE SJ , Black A, Kreimer AR, Duggan MA, et al
Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MONK BJ , Sill MW, Hanjani P, Edwards R, et al
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

XU B , Hamada S, Kusuki I, Itoh R, et al
Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

EMONS G , Kaufmann M, Gorchev G, Tsekova V, et al
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
Gynecol Oncol. 2010;119:457-61.
PubMed Text format Related articles Abstract available

November 2010

VINEYARD MA , Daniels MS, Urbauer DL, Deavers MT, et al
Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

FLEMING ND , Lentz SE, Cass I, Li AJ, et al
Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ZHOU Y , Irwin ML, Risch HA
Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WANG FQ , Fisher J, Fishman DA
MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GONZALEZ BOSQUET J , Peedicayil A, Maguire J, Chien J, et al
Comparison of gene expression patterns between avian and human ovarian cancers.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ALCAZAR JL , Jurado M
Three-dimensional ultrasound for assessing women with gynecological cancer: A systematic review.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

JENSEN SE , Rosenbloom SK, Beaumont JL, Abernethy A, et al
A new index of priority symptoms in advanced ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HEUBNER M , Wimberger P, Dahlmann B, Kasimir-Bauer S, et al
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KUNOS CA , Sill MW, Buekers TE, Walker JL, et al
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HARMANDAYAN GZ , Gao F, Mutch DG, Virgo KS, et al
Ovarian cancer patient surveillance after curative-intent initial treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

CLINKARD DJ , Khalifa M, Osborned RJ, Bouffet E, et al
Successful management of medulloblastoma arising in an immature ovarian teratoma in pregnancy.
Gynecol Oncol. 2010.
PubMed Text format Related articles

LIGGETT TE , Melnikov A, Yi Q, Replogle C, et al
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ROSE PG , Monk BJ, Provencher D, Hartney J, et al
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BURTON E , Chase D, Yamamoto M, de Guzman J, et al
Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BANSAL N , Hoffman M
Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab.
Gynecol Oncol. 2010.
PubMed Text format Related articles

October 2010

RHO SB , Kim BR, Kang S
A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KANG S , Kim TJ, Seo SS, Kim BG, et al
Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LEE JW , Park YA, Choi JJ, Lee YY, et al
The expression of the miRNA-200 family in endometrial endometrioid carcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HAN JJ , Yu M, Houston N, Steinberg SM, et al
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HOLLOWAY RW , Brudie LA, Rakowski JA, Ahmad S, et al
Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: Description of technique.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HOSKINS PJ , Le N, Correa R
CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LONG KC , Levinson KL, Diaz JP, Gardner GJ, et al
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LASSUS H , Staff S, Leminen A, Isola J, et al
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HUSSEINZADEH N
Status of tumor markers in epithelial ovarian cancer has there been any progress? A review.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ALETTI GD , Eisenhauer EL, Santillan A, Axtell A, et al
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

VERGOTE I , Amant F, Leunen K
Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?
Gynecol Oncol. 2010;119:1-2.
PubMed Text format Related articles

September 2010

KOTHARI R , Nagel C, Koopmeiners JS, Ivy JJ, et al
The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HAN ES , Burger RA, Darcy KM, Sill MW, et al
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LI J , Liang S, Yu H, Zhang J, et al
An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

NAKAYAMA K , Rahman MT, Rahman M, Yeasmin S, et al
Biological role and prognostic significance of NAC1 in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BAE-JUMP VL , Zhou C, Boggess JF, Whang YE, et al
Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

CRAMER DW , Vitonis AF, Welch WR, Terry KL, et al
Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HURTEAU JA , Brady MF, Darcy KM, McGuire WP, et al
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluat
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TAYLOR-HARDING B , Orsulic S, Karlan BY, Li AJ, et al
Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BLANK SV , Christos P, Curtin JP, Goldman N, et al
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

OTSUKA I , Uno M, Wakabayashi A, Kameda S, et al
Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LOSE F , Nagle CM, O'Mara T, Batra J, et al
Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ANGELUCCI A , Mari M, Millimaggi D, Giusti I, et al
Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WANG B , Kaumaya PT, Cohn DE
Immunization with synthetic VEGF peptides in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TERRY KL , Tworoger SS, Goode EL, Gates MA, et al
MTHFR polymorphisms in relation to ovarian cancer risk.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ARORA S , Bisanz KM, Peralta LA, Basu GD, et al
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Gynecol Oncol. 2010;118:220-7.
PubMed Text format Related articles Abstract available

VICUS D , Shaw PA, Finch A, Rosen B, et al
Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
Gynecol Oncol. 2010;118:295-8.
PubMed Text format Related articles Abstract available

GABRA H
Back to the future: Targeting molecular changes for platinum resistance reversal.
Gynecol Oncol. 2010;118:210-1.
PubMed Text format Related articles

August 2010

PEIRETTI M , Zanagnolo V, Aletti GD, Bocciolone L, et al
Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

VAN ALTENA AM , Kolwijck E, Spanjer MJ, Hendriks JC, et al
CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SENTURK E , Cohen S, Dottino PR, Martignetti JA, et al
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ZAPARDIEL I , Rosenberg P, Peiretti M, Zanagnolo V, et al
The role of restaging borderline ovarian tumors: Single institution experience and review of the literature.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BASHIR S , Gerardi MA, Giuntoli RL 2nd, Montes TP, et al
Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SCHEIL-BERTRAM S , Tylus-Schaaf P, du Bois A, Harter P, et al
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ROQUE DM , Jones DF, Carter G, Kelley JL, et al
Primary giant cell malignant fibrous histiocytoma of the ovary: Case report and review of the literature.
Gynecol Oncol. 2010.
PubMed Text format Related articles

SHIH KK , Zhou QC, Aghajanian C, Huh J, et al
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SAKURAI M , Shibata K, Umezu T, Kajiyama H, et al
Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SCHORGE JO , Coleman RL, Cohn DE, Kauff ND, et al
SGO White Paper Ovarian Education Campaign [INTRODUCTORY PARAGRAPH-Herzog/Coleman] Project I-Background, Screening & Surveillance.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ZHU M , Fejzo MS, Anderson L, Dering J, et al
Periostin promotes ovarian cancer angiogenesis and metastasis.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

QUINN M
Progress in ovarian cancer trials: The GCIG consensus model - Is bigger, better?
Gynecol Oncol. 2010.
PubMed Text format Related articles

BAKHRU A , Mallinger JB, Buckanovich RJ, Griggs JJ, et al
Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: A study from the NHANES.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KARUBE Y , Fujimoto T, Takahashi O, Nanjyo H, et al
Histopathological prognostic factors predicting para-aortic lymph node metastasis in patients with endometrioid uterine cancer.
Gynecol Oncol. 2010;118:151-4.
PubMed Text format Related articles Abstract available

July 2010

SHAHABI S , Yang CP, Goldberg GL, Horwitz SB, et al
Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MODESITT SC , Parsons SJ
In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GELLER MA , Downs LS, Judson PL, Ghebre R, et al
Learning about ovarian cancer at the time of diagnosis: Video versus usual care.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DEWDNEY SB , Rimel BJ, Reinhart AJ, Kizer NT, et al
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SEIDMAN JD , Cosin JA, Wang BG, Alsop S, et al
Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: A clinicopathologic study of 84 patients originally classified as FIGO stage II.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HUANG M , Chadha M, Musa F, Friedmann P, et al
Lymph nodes: Is total number or station number a better predictor of lymph node metastasis in endometrial cancer?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MIRZA MR , Lund B, Lindegaard JC, Keldsen N, et al
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

AKTAS D , Gultekin M, Kabacam S, Alikasifoglu M, et al
Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BEVIS KS , Buchsbaum DJ, Straughn JM Jr
Overcoming TRAIL resistance in ovarian carcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

FOTOPOULOU C , Savvatis K, Braicu EI, Brink-Spalink V, et al
Adult granulosa cell tumors of the ovary: Tumor dissemination pattern at primary and recurrent situation, surgical outcome.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

CORREA DD , Zhou Q, Thaler HT, Maziarz M, et al
Cognitive functions in long-term survivors of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LI Z , Hu S, Wang J, Cai J, et al
MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GHOSH S , Albitar L, Lebaron R, Welch WR, et al
Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

CHI DS , Zivanovic O, Levinson KL, Kolev V, et al
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SILVAGNO F , Poma CB, Realmuto C, Ravarino N, et al
Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MANGILI G , Scarfone G, Gadducci A, Sigismondi C, et al
Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

June 2010

ARRIBA LN , Fader AN, Frasure HE, von Gruenigen VE, et al
A review of issues surrounding quality of life among women with ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LEDERMANN JA , Raja FA
Targeted trials in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

FREEDMAN OC , Dodge J, Shaw P, Oza AM, et al
Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LURIE G , Wilkens LR, Thompson PJ, Matsuno RK, et al
Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: A case analysis.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

FRIEDLANDER M , Hancock KC, Rischin D, Messing MJ, et al
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

COHEN M , Dromard M, Petignat P
Heat shock proteins in ovarian cancer: A potential target for therapy.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

RAY-COQUARD I , Weber B, Lotz JP, Tournigand C, et al
Management of rare ovarian cancers: The experience of the French website <<Observatory for rare malignant tumours of the ovaries>> by the GINECO group: Interim analysis of the first 100 patients.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ESCOBAR PF , Starks DC, Fader AN, Barber M, et al
Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: Surgical outcomes and learning curve analysis.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

STAFF AC , Bock AJ, Becker C, Kemp T, et al
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BRISTOW RE , Palis BE, Chi DS, Cliby WA, et al
The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HIRTE H , Oza A, Swenerton K, Ellard SL, et al
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WOLF AM , Rumpold H, Reimer D, Marth C, et al
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SAUNDERS BA , Podzielinski I, Ware RA, Goodrich S, et al
Risk of malignancy in sonographically confirmed septated cystic ovarian tumors.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TIERSTEN AD , Sill MW, Knight D, Muggia F, et al
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: A feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: A Gynecologic Oncology Group study.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WEBB JR , Wick DA, Nielsen JS, Tran E, et al
Profound elevation of CD8(+) T cells expressing the intraepithelial lymphocyte marker CD103 (alpha(E)/beta(7) Integrin) in high-grade serous ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KIM HS , Park CY, Lee JM, Lee JK, et al
Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: A multi-center study.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

RATNER ES , Tuck D, Richter C, Nallur S, et al
MicroRNA signatures differentiate uterine cancer tumor subtypes.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ARORA S , Bisanz KM, Peralta LA, Basu GD, et al
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

NOLEN B , Velikokhatnaya L, Marrangoni A, De Geest K, et al
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
Gynecol Oncol. 2010;117:440-5.
PubMed Text format Related articles Abstract available

May 2010

TOMINAGA EI , Tsuda H, Arao T, Nishimura S, et al
Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

RICE LW
Hormone prevention strategies for breast, endometrial and ovarian cancers.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SMERDEL MP , Steffensen KD, Waldstrom M, Brandslund I, et al
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

JAZAERI AA , Ferriss JS, Bryant JL, Dalton MS, et al
Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

PREVIDI S , Malek A, Albertini V, Riva C, et al
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LIM MC , Park SH, Park SY
Ovarian clear cell carcinoma: High risk of venous thromboembolism.
Gynecol Oncol. 2010.
PubMed Text format Related articles

COSTI MP , Zeillinger R
Drug resistance in ovarian cancer: biomarkers and treatments Highlights from the DROC meeting held in Modena (Italy) on the 19th and 20th of February 2009. Scientific topics discussed at the meeting are reported in the present issue.
Gynecol Oncol. 2010;117:149-51.
PubMed Text format Related articles

CADRON I , Van Gorp T, Mihalyi A, Luyten C, et al
The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GOMEZ-RAPOSO C , Mendiola M, Barriuso J, Hardisson D, et al
Molecular characterization of ovarian cancer by gene-expression profiling.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

April 2010

ASADOLLAHI R , Hyde CA, Zhong XY
Epigenetics of ovarian cancer: From the lab to the clinic.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

KANG S , Dong SM, Park NH
Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MARKMAN M
Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: Time for an evidence-based comparison.
Gynecol Oncol. 2010.
PubMed Text format Related articles

PECTASIDES D , Pectasides E, Papaxoinis G, Psyrri A, et al
Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

JEONG NH , Lee JM, Lee JK, Kim JW, et al
Role of body mass index as a risk and prognostic factor of endometrioid uterine cancer in Korean women.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MCLEAN KA , Shah CA, Thompson SA, Gray HJ, et al
Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

RICHARDSON DL , Backes FJ, Hurt JD, Seamon LG, et al
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SHIH IEM
Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter?
Gynecol Oncol. 2010;117:1-3.
PubMed Text format Related articles

CASS I , Walts A, Karlan BY
Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
Gynecol Oncol. 2010;117:27-31.
PubMed Text format Related articles Abstract available

WANG FQ , Ariztia EV, Boyd LR, Horton FR, et al
Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity.
Gynecol Oncol. 2010;117:88-95.
PubMed Text format Related articles Abstract available

RANDALL LM , Monk BJ
Bevacizumab toxicities and their management in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

March 2010

FRUMOVITZ M , Schmeler KM, Malpica A, Sood AK, et al
Unmasking the complexities of mucinous ovarian carcinoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BEGUM FD , Hogdall E, Christensen IJ, Christensen L, et al
Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DARCY KM , Birrer MJ
Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WANG R , Zhang T, Ma Z, Wang Y, et al
The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

EL-GAZZAR A , Wittinger M, Perco P, Anees M, et al
The role of c-FLIP(L) in ovarian cancer: Chaperoning tumor cells from immunosurveillance and increasing their invasive potential.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

JUANG CM , Yen MS, Chao KC
Reply to Dr. Markman on "Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"
Gynecol Oncol. 2010.
PubMed Text format Related articles

DESPIERRE E , Lambrechts D, Neven P, Amant F, et al
The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DE MARZI P , Frigerio L, Cipriani S, Parazzini F, et al
Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience.
Gynecol Oncol. 2010;116:408-12.
PubMed Text format Related articles Abstract available

SHIH KK , Chi DS, Barakat RR, Leitao MM Jr, et al
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2010;116:364-9.
PubMed Text format Related articles Abstract available

GONZALEZ BOSQUET J , Terstriep SA, Cliby WA, Brown-Jones M, et al
The impact of multi-modal therapy on survival for uterine carcinosarcomas.
Gynecol Oncol. 2010;116:419-23.
PubMed Text format Related articles Abstract available

MILLER DA , Richardson S, Grigsby PW
A new method of anatomically conformal vaginal cuff HDR brachytherapy.
Gynecol Oncol. 2010;116:413-8.
PubMed Text format Related articles Abstract available

February 2010

PILS D , Wittinger M, Petz M, Gugerell A, et al
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-ss treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

SHIH KK , Chi DS, Barakat RR, Leitao MM Jr, et al
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

POLLOCK J
Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence"
Gynecol Oncol. 2010.
PubMed Text format Related articles

ROSE PG , Tian C, Bookman MA
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

CHENG L , Lu W, Kulkarni B, Pejovic T, et al
Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ANSENBERGER K , Richards C, Zhuge Y, Barua A, et al
Decreased severity of ovarian cancer and increased survival in hens fed a flaxseed-enriched diet for 1 year.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TANNER EJ , Chi DS, Eisenhauer EL, Diaz-Montes TP, et al
Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MARKMAN M
"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"
Gynecol Oncol. 2010.
PubMed Text format Related articles

YIGIT R , Massuger LF, Figdor CG, Torensma R, et al
Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

LOU E , Hensley ML, Lassman A, Aghajanian C, et al
Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma.
Gynecol Oncol. 2010.
PubMed Text format Related articles

HELLEMAN J , Smid M, Jansen MP, van der Burg ME, et al
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

PAUTIER P , Joly F, Kerbrat P, Bougnoux P, et al
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Gynecol Oncol. 2010;116:157-62.
PubMed Text format Related articles Abstract available

CAPO-CHICHI CD , Yeasky TM, Heiber JF, Wang Y, et al
Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Gynecol Oncol. 2010;116:269-75.
PubMed Text format Related articles Abstract available

ROCHE MR , Rudd PJ, Krasner CN, Matulonis UA, et al
Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors.
Gynecol Oncol. 2010;116:168-72.
PubMed Text format Related articles Abstract available

January 2010

MAY T , Virtanen C, Sharma M, Milea A, et al
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MERCADO C , Zingmond D, Karlan BY, Sekaris E, et al
Quality of care in advanced ovarian cancer: The importance of provider specialty.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BYRON SA , Gartside MG, Wellens CL, Goodfellow PJ, et al
FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

VICUS D , Beiner ME, Klachook S, Le LW, et al
Pure dysgerminoma of the ovary 35 years on: A single institutional experience.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DI GIORGIO A , Cardi M, Sammartino P
Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: An argued role.
Gynecol Oncol. 2010.
PubMed Text format Related articles

DRENBERG CD , Saunders BO, Wilbanks GD, Chen R, et al
Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ROSE SL , Kunnimalaiyaan M, Drenzek J, Seiler N, et al
Notch 1 signaling is active in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

JOBSEN JJ , Ten Cate LN, Lybeert ML, van der Steen-Banasik EM, et al
The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

STEFFENSEN KD , Waldstrom M, Brandslund I, Jakobsen A, et al
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GUARNERI V , Piacentini F, Barbieri E, Conte PF, et al
Achievements and unmet needs in the management of advanced ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DANGSUWAN P , Manchana T
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

December 2009

WALSH CS , Blum A, Walts A, Alsabeh R, et al
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DIAZ JP , Tew WP, Zivanovic O, Konner J, et al
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

November 2009

DIAZ JP , Abu-Rustum NR, Sonoda Y, Downey RJ, et al
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ROCERETO TF , Brady WE, Shahin MS, Hoffman JS, et al
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DUSKA LR , Garrett L, Henretta M, Ferriss JS, et al
When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

AUNER V , Sehouli J, Oskay-Oezcelik G, Horvat R, et al
ABC transporter gene expression in benign and malignant ovarian tissue.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

O'DONNELL JD , Linger RJ, Kruk PA
BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.
Design: